We only evaluated the diagnostic value of uEVEpCAM-CD9 in PCa, and it has not been evaluated in depth in other aspects, e.g., as a predictor in the development of castration-resistant prostate cancer (CRPC), an indicator for successful radiotherapy and chemotherapy. Here, CD9 is linked to posterior cortical atrophy.